Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Study ID
NCT06479460
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • ctDNA-MRD — DIAGNOSTIC_TEST
    This study is an observational non intervention study that only tests peripheral blood samples from different treatment nodes of the subjects, without interfering with the normal clinical diagnosis and treatment process of the patients.

Study Details

1. To explore the predictive value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population; 2. To evaluate the prognostic value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population.

Key Dates

First listed
Jun 28, 2024
Start date
Mar 8, 2024
Status verified
Jul 2024
Primary completion
May 31, 2025
Completion
Mar 31, 2026

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Postoperative pathological pCR rate [ Time Frame: 2024.3 -- 2026. 3 ]

Central Contacts

  • Zhihone Zhang, Doctor of Medicine
    18013348615
    [email protected]
  • Jing Wu, Doctor of Medicine
    18013348615

Find similar trials

Nationwide
Breast cancer trialsOncology trialsBreast oncology trialsWomen's health trials

Related Studies